scholarly journals Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

2019 ◽  
Vol 20 (4) ◽  
pp. 556-569 ◽  
Author(s):  
Bertrand Tombal ◽  
Fred Saad ◽  
David Penson ◽  
Maha Hussain ◽  
Cora N Sternberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Patient Reported Outcomes ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant ◽  
Patient Reported

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

The Lancet ◽  
2021 ◽  
Vol 398 (10295) ◽  
pp. 131-142
Author(s):  
Christopher Sweeney ◽  
Sergio Bracarda ◽  
Cora N Sternberg ◽  
Kim N Chi ◽  
David Olmos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant

scholarly journals Management of Enzalutamide Related Adverse Events for Castration Resistant Prostate Cancer by Patient Reported Outcomes

2016 ◽  
Vol 27 ◽  
pp. vii78-vii79
Author(s):  
Taro Iguchi ◽  
Sayaka Yasuda ◽  
Minoru Kato ◽  
Takeshi Yamazaki ◽  
Satoshi Tamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adverse Events ◽  
Patient Reported Outcomes ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Patient Reported

Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS5081-TPS5081 ◽  
Author(s):  
James L. Gulley ◽  
Jeannie Lorraine Giacchino ◽  
James Bradley Breitmeyer ◽  
Alexis J. Franzusoff ◽  
Dennis Panicali ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Efficacy Study ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document